Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

• Status: Completed
• Trial end date: 2015-10-09
• Target enrollment: 0
• Participant gender: All

Summary

Adults with Crohn's disease that is clinically active despite conventional treatment will be eligible for this study. Patients may receive one of three doses of PF-00547659 (experimental drug) or placebo (inactive drug). Disease activity will be measured every two weeks.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer; Shire

Criteria

Inclusion Criteria:

• Subjects must have failed or are intolerant to anti-TNFs and/or immunosuppressants (AZA, 6-MP, and/or MTX).

• hsCRP greater than 3mg/L

• Ulcerations demonstrated by colonoscopy performed during screening or 8 weeks prior to screening

Exclusion Criteria:

• Pregnant or breast feeding

• Short bowel syndrome due to multiple small bowel resections

• Presence of a stoma